TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical ...

A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (TEVA-0.65%) well higher on Monday. The company, known for being a top producer ...

The move comes as Teva enters the “Acceleration Phase” of its"Pivot to Growth" restructuring strategy the company unveiled in early 2023, CEO Richard Francis said in a statement.

In addition to encouraging adventure, For Playground Earth emphasizes conservation. Teva has partnered with Leave No Trace to support outdoor stewardship initiatives, donating $100,000 to amplify ...

Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron ...

Teva’s generics business is growing as well, with spikes in 2024 of 15% in the US, 6% in Europe, and 15% in international markets compared to the previous year. Stacking wins. Despite the mixed ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well ...

The European Union fined Israel’s Teva Pharmaceutical 462.6 million euros, saying it abused its market position in a way that might have delayed competitors from entering the multiple sclerosis ...